Altamira Therapeutics Ltd (CYTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-1996 | 09-1996 | 06-1996 | 03-1996 | 12-1995 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -23,766 | -16,651 | -11,079 | -5,800 | -72,520 |
| Depreciation Amortization | 1,515 | 1,118 | 744 | 415 | 1,546 |
| Other Working Capital | -3,229 | -4,866 | -3,558 | -1,869 | -4,208 |
| Other Operating Activity | 521 | 0 | 207 | 103 | 49,458 |
| Operating Cash Flow | $-24,959 | $-20,399 | $-13,686 | $-7,151 | $-25,724 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -886 | -614 | -533 | -118 | -595 |
| Net Acquisitions | 0 | 0 | -3,891 | -3,928 | 6,992 |
| Other Investing Activity | -12,840 | -14,280 | 0 | 0 | -1,550 |
| Investing Cash Flow | $-13,726 | $-14,894 | $-4,424 | $-4,046 | $4,847 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | 31,430 | 22,220 | 10,932 | 5,759 | 40,728 |
| Financing Cash Flow | $31,430 | $22,220 | $10,932 | $5,759 | $40,728 |
| Beginning Cash Position | 27,551 | 27,551 | 27,551 | 27,551 | 7,700 |
| End Cash Position | 20,296 | 14,478 | 20,373 | 22,113 | 27,551 |
| Net Cash Flow | $-7,255 | $-13,073 | $-7,178 | $-5,438 | $19,851 |
| Free Cash Flow | |||||
| Operating Cash Flow | -24,959 | -20,399 | -13,686 | -7,151 | -25,724 |
| Free Cash Flow | -24,959 | -20,399 | -13,686 | -7,151 | -25,724 |